Rituximab for auto-immune alveolar proteinosis, a real life cohort study

Rituximab for auto-immune alveolar proteinosis, a real life cohort study

Abstract Background Whole lung lavage is the current standard therapy for pulmonary alveolar proteinosis (PAP) that is characterized by the alveolar accumulation of surfactant. Rituximab showed promising results in auto-immune PAP (aPAP) related to anti-GM-CSF antibody. Methods We aimed to assess ef...

Full description

Bibliographic Details
Main Authors: Berenice Soyez, Raphael Borie, Cedric Menard, Jacques Cadranel, Leonidas Chavez, Vincent Cottin, Emmanuel Gomez, Sylvain Marchand-Adam, Sylvie Leroy, Jean-Marc Naccache, Hilario Nunes, Martine Reynaud-Gaubert, Laurent Savale, Abdellatif Tazi, Lidwine Wemeau-Stervinou, Marie-Pierre Debray, Bruno Crestani
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Respiratory Research
Subjects:
Whole lung lavage
GM-CSF
Surfactant
Interstitial lung disease
Therapy
Online Access:http://link.springer.com/article/10.1186/s12931-018-0780-5

Internet

http://link.springer.com/article/10.1186/s12931-018-0780-5

Similar Items